In this context, the literature shows that the response to conventional cancer treatment is worse when malignant lesions present the expression of these molecules,9 since the PD-1/PD-L1 interaction pathway protects the tumor against attacks, mediated by the immune response, and increases the possibility of malignancy. Here, PDCD1 is linked to cancer.